IS5809A - Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration - Google Patents

Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration

Info

Publication number
IS5809A
IS5809A IS5809A IS5809A IS5809A IS 5809 A IS5809 A IS 5809A IS 5809 A IS5809 A IS 5809A IS 5809 A IS5809 A IS 5809A IS 5809 A IS5809 A IS 5809A
Authority
IS
Iceland
Prior art keywords
acat
treatment
mmp inhibitors
concomitant administration
fat degeneration
Prior art date
Application number
IS5809A
Other languages
Icelandic (is)
Inventor
Michael Andrew Bocan Thomas
Original Assignee
Warner-Lambert Company, , Delaware Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company, , Delaware Corporation filed Critical Warner-Lambert Company, , Delaware Corporation
Publication of IS5809A publication Critical patent/IS5809A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
IS5809A 1998-07-21 2001-01-12 Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration IS5809A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
IS5809A true IS5809A (en) 2001-01-12

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5809A IS5809A (en) 1998-07-21 2001-01-12 Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration

Country Status (25)

Country Link
EP (1) EP1098662A2 (en)
JP (1) JP2002521328A (en)
KR (1) KR20010083134A (en)
CN (1) CN1310629A (en)
AP (1) AP2001002035A0 (en)
AU (1) AU4701799A (en)
BG (1) BG105162A (en)
BR (1) BR9912296A (en)
CA (1) CA2335062A1 (en)
CZ (1) CZ2001126A3 (en)
EA (1) EA200100153A1 (en)
EE (1) EE200100046A (en)
HR (1) HRP20010055A2 (en)
HU (1) HUP0102880A3 (en)
ID (1) ID30030A (en)
IL (1) IL140982A0 (en)
IS (1) IS5809A (en)
NO (1) NO20010291L (en)
OA (1) OA11584A (en)
PL (1) PL346011A1 (en)
SK (1) SK502001A3 (en)
TR (1) TR200100205T2 (en)
WO (1) WO2000004892A2 (en)
YU (1) YU3501A (en)
ZA (1) ZA200100294B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (en) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Prevention of plaque rupure by ACAT inhibitors
DOP2000000107A (en) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND LENGTH OF NEURONS
CA2393825A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
BR0113523A (en) * 2000-09-01 2004-06-29 Sankyo Co Pharmaceutical composition, kit, and uses of n- (1-octyl-5-carboxymethyl) -4,6-dimethyl-indolin-7-yl) -2,2-dimethyl-propanamide or a pharmacologically acceptable salt thereof , and a composition
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
AU2003229883B2 (en) * 2002-04-03 2009-06-11 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
WO2004007444A2 (en) * 2002-07-11 2004-01-22 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (en) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 Use of group of carbamyl phenylsulfonyl compounds
EP3244883A1 (en) * 2015-01-15 2017-11-22 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (en) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 The effective extract component of river hazel and its application in prevention and treatment atherosclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
JPH11510184A (en) * 1995-08-04 1999-09-07 ワーナー−ランバート・コンパニー Use of sulfamic acid derivatives, acylsulfonamides or sulfonyl carbamates for the manufacture of a medicament for reducing lipoprotein levels
WO1997044315A1 (en) * 1996-05-17 1997-11-27 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
EP0931045A1 (en) * 1996-09-04 1999-07-28 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
IL140982A0 (en) 2002-02-10
AU4701799A (en) 2000-02-14
PL346011A1 (en) 2002-01-14
SK502001A3 (en) 2002-06-04
NO20010291D0 (en) 2001-01-18
BR9912296A (en) 2001-04-17
EE200100046A (en) 2002-06-17
AP2001002035A0 (en) 2001-03-31
HRP20010055A2 (en) 2002-04-30
HUP0102880A2 (en) 2002-06-29
CZ2001126A3 (en) 2002-01-16
WO2000004892A2 (en) 2000-02-03
ID30030A (en) 2001-11-01
HUP0102880A3 (en) 2002-11-28
NO20010291L (en) 2001-01-18
WO2000004892A3 (en) 2000-05-18
JP2002521328A (en) 2002-07-16
CN1310629A (en) 2001-08-29
CA2335062A1 (en) 2000-02-03
BG105162A (en) 2001-12-29
EA200100153A1 (en) 2001-08-27
KR20010083134A (en) 2001-08-31
YU3501A (en) 2005-06-10
TR200100205T2 (en) 2001-05-21
ZA200100294B (en) 2002-01-10
OA11584A (en) 2004-07-20
EP1098662A2 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
IS5405A (en) Prostaglandin agonists and their use in the treatment of bone disorders
IS2457B (en) Compositions of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders
IS6560A (en) Pharmaceutical composition for the treatment of acute, persistent pain and / or nervous system pain and migraine
IS5500A (en) Medicinal preparations for the stimulation and treatment of gastrointestinal disorders and related diseases
NO20005190L (en) Therapeutic angiogenic factors and methods for their use
NO994613D0 (en) Procedures and preparations for the treatment of sleep apnea
DK0965578T3 (en) Hitherto unknown triglycerics and preparations which comprise this
NO990296D0 (en) The HPPD gene and inhibitors
NO20011964L (en) Well treatment fluids and methods for using them
DK0927555T3 (en) Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia
NO993868D0 (en) 3-piperidyl-4-oxoquinazoline derivatives and medical preparations containing them
IS5898A (en) 5HT1 receptor agonists and metoclopramide for the treatment of migraine
IS5233A (en) Diagnosis of reward deficiency syndrome and its preparations
IS5220A (en) Cyclo-oxygenase-2 selective carprofen for the treatment of pain and inflammation in dogs
NO983576D0 (en) Well treatment fluids and methods
IS5809A (en) Concomitant administration of ACAT and MMP inhibitors for the treatment of fat degeneration
NO20002181D0 (en) Sterilization wrap, its use and method of sterilization
DK1041985T3 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for the treatment of prophylactic disorders
AU2001292019A1 (en) Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
NO20010464L (en) Methods and Preparations for the Treatment of Gastroesophageal Reflux Syndrome
DK1017388T3 (en) Pharmaceuticals containing ibuprofen and domperidone for the treatment of migraine
NO20012738D0 (en) Therapeutic products and their use
IS6707A (en) Preparation for the prevention and treatment of cancer
NO20013816D0 (en) Benzamide derivatives and drugs containing them
DK1032559T3 (en) Aminoalkylphenol derivatives for the treatment of depression and memory failure